MARKHAM, Ontario, June 4, 2013 /PRNewswire/ -- Axxess Pharma Inc.
(OTC Pink: AXXE), a pharmaceutical company specializing in the
marketing and distribution of both prescription and
non-prescription medical products, is pleased to announce the
Company is now current in their filings on OTCMarkets.com. The
Company is now listed on the OTC Markets website as "Current
Information" status. This upgraded listing is expected to increase
transparency and investor confidence.
Dr. Daniel Bagi, CEO of Axxess
Pharma, Inc. stated, "We are pleased to have accomplished this task
for our shareholders. We remain focused on complete
transparency and generating revenues by the second half of 2013. As
the weeks and months progress, we will continue to release news
regarding product licensing, product distribution, revenues, and
brand marketing." Dr. Bagi further stated, "During the last 15
months, the company has worked diligently to bolster management,
and initiate revenues and profits through our prescription drugs
and over-the-counter nutritional supplements."
For more information, please visit www.axxesspharmainc.com, or
contact the Company at (416) 410-6006.
About Axxess Pharma, Inc.:
Axxess Pharma Inc. is a Nevada Corporation operating through its
wholly-owned Canadian Subsidiary: Axxess Pharma Canada Inc.,
headquartered in Toronto. Axxess is a specialty Health Care
Products Company dedicated to improving health and quality of life
by offering select medicines, nutritional supplements and
over the counter remedies all across the Americas. Axxess's goal is
to bring additional products to the market and provide new,
innovative options for better health spanning areas such as high
cholesterol, blood pressure, acute pain, - to optimal health
management through improved nutritional supplements.
Safe Harbor Statement:
Statements about the Company's future expectations and all other
statements in this press release other than historical facts, are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created
thereby.
The above information contains information relating to the
Company that is based on the beliefs of the Company and/or its
management, as well as assumptions made by any information
currently available to the Company or its management. When used in
this document, the words "anticipate," "estimate," "expect,"
"intend," "plans," "projects," and similar expressions, as they
relate to the Company or its management, are intended to identify
forward-looking statements. Such statements reflect the current
view of the Company regarding future events and are subject to
certain risks, uncertainties and assumptions, including the risks
and uncertainties noted. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
to be incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated, expected,
intended or projected. In each instance, forward-looking
information should be considered in light of the accompanying
meaningful cautionary statements herein. Factors that could cause
results to differ include, but are not limited to, successful
performance of internal plans, the impact of competitive services
and pricing and general economic risks and uncertainties.
Contact:
Axxess Pharma, Inc.
Daniel Bagi,
M.D., CEO
Phone Number (416) 410-6006
danielb@axxesspharmainc.com
www.axxesspharmainc.com
SOURCE Axxess Pharma Inc.